| Literature DB >> 29090241 |
Ryunosuke Hakuta1,2, Tsuyoshi Hamada1,3, Yousuke Nakai1, Hiroyuki Isayama1, Hirofumi Kogure1, Suguru Mizuno1, Takahara Naminatsu1, Hiroshi Yagioka4, Osamu Togawa5, Saburo Matsubara1, Yukiko Ito2, Natsuyo Yamamoto6, Takeshi Tsujino2,7, Kazuhiko Koike1.
Abstract
BACKGROUND AND STUDY AIMS: Endoscopic papillary balloon dilation (EPBD) is a method of bile duct stone removal that has a better long-term outcome but a high risk of post-ERCP pancreatitis (PEP). Recent studies have suggested that 5-minute EPBD can reduce the incidence of PEP. This study aimed to examine the safety and effectiveness of longer duration EPBD compared with shorter duration EPBD (5 minutes vs. 15 seconds after disappearance of the waist of a dilation catheter). PATIENTS AND METHODS: Patients without a history of endoscopic sphincterotomy or EPBD who underwent EPBD to remove bile duct stones were selected retrospectively from five centers. The incidence of PEP, other early adverse events, and outcomes of EPBD were compared between the groups. A multivariable analysis of risk factors for PEP was performed.Entities:
Year: 2017 PMID: 29090241 PMCID: PMC5658216 DOI: 10.1055/s-0043-118479
Source DB: PubMed Journal: Endosc Int Open ISSN: 2196-9736
Fig. 1Flowchart of patient selection into the 5-minute and 15-second EPBD groups for removal of bile duct stones. EPBD, endoscopic papillary balloon dilation; EST, endoscopic sphincterotomy.
Baseline characteristics of the 5-minute and 15-second EPBD for removal of bile duct stones.
|
|
|
| |
| Sex, male/female | 106/51 (67.5/32.5) | 272/178 (60.4/39.6) | 0.126 |
| Age, years | 75 (26 – 99, 64 – 81) | 73.5 (10 – 100, 64 – 81) | 0.510 |
| ASA-PS, 1/2/3/4 | 32/90/35/0 | 140/236/71/3 | 0.027 |
| Periampullary diverticulum | 49 (31.2) | 182 (40.4) | 0.045 |
| Gallbladder stone | 116 (73.9) | 274 (60.9) | 0.004 |
| Previous cholecystectomy | 17 (10.8) | 60 (13.3) | 0.487 |
| Stone diameter, mm | 5 (1 – 20, 4 – 7) | 6 (1 – 36, 4 – 9) | 0.005 |
| Number of stones | 1 (1 – 20, 1 – 3) | 2 (1 – 36, 1 – 3) | 0.050 |
| Bile duct diameter, mm | 9 (4 – 20, 8 – 11) | 10 (3 – 28, 8 – 12) | < 0.001 |
| Dilation balloon diameter, | 2/37/85/33 | 3/74/318/55 | < 0.001 |
| Peak pressure of the balloon, atmospheres | 2 (0.5 – 7, 2 – 3) | 3 (1 – 8, 2 – 4) | < 0.001 |
Data are expressed as numbers and percentages of patients within a given group or as medians (range, interquartile range). ASA-PS, American Society of Anesthesiologists Physical Status Classification System score; EPBD, endoscopic papillary balloon dilation.
Outcomes of the 5-minute and 15-second EPBD groups.
|
|
|
| |
| Use of lithotripsy | 13 (8.3) | 90 (20.0) | < 0.001 |
EML | 13 (8.3) | 89 (19.8) | < 0.001 |
ESWL | 1 (0.6) | 2 (0.4) | |
EHL | 1 (0.6) | 1 (0.2) | |
| Procedure time during the first session, minutes | 45.0 (18.0 – 132, 35.0 – 57.0) | 37.0 (10.0 – 114, 30.0 – 50.0) | < 0.001 |
| Procedure time excluding balloon time, minutes | 40.0 (13.0 – 127, 30.0 – 52.0) | 36.7 (9.7 – 114, 29.7 – 49.7) | 0.412 |
| Complete stone removal during a single session | 135 (86.0) | 327 (72.7) | < 0.001 |
| Overall complete stone removal | 156 (99.4) | 438 (97.3) | 0.201 |
|
Number of ERCP sessions
| 0.002 | ||
1 | 135 (86.0) | 333 (74.0) | |
2 | 19 (12.1) | 100 (22.2) | |
≥ 3 | 3 (1.9) | 17 (3.8) |
Data are expressed as numbers and percentages of patients within a given group or as medians (range, interquartile range). EHL, electrohydraulic lithotripsy; EML, endoscopic mechanical lithotripsy; EPBD, endoscopic papillary balloon dilation; ERCP, endoscopic retrograde cholangiopancreatography; ESWL, extra shock wave lithotripsy.
The Wilcoxon rank sum test was used to estimate differences in the number of ERCP sessions between the groups.
Procedures in the 5-minute and 15-second EPBD groups.
|
|
|
| |
| Pancreatic duct opacification | 17 (10.9) | 62 (13.8) | 0.409 |
| Main pancreatic duct/ | 10/7/0/0 | 24/29/6/3 | 0.498 |
|
Guidewire insertion into the pancreatic duct
| 63 (41.7) | 154 (40.5) | 0.845 |
|
Number of guidewire insertions into the pancreatic duct (in cases of guidewire insertion)
| 2 (1 – 10, 1 – 5) | 2 (1 – 40, 1 – 4) | 0.722 |
| Difficult cannulation | 34 (23.3) | 105 (26.4) | 0.507 |
| ERCP performed by trainees | 107 (70.4) | 230 (51.2) | < 0.001 |
| NSAIDs | 56 (36.8) | 6 (1.3) | < 0.001 |
| Pancreatic stent | 11 (7.2) | 48 (10.7) | 0.270 |
Data are expressed as numbers and percentages of patients within a given group or as medians (range, interquartile range). EPBD, endoscopic papillary balloon dilation; ERCP, endoscopic retrograde cholangiopancreatography; NSAIDs, nonsteroidal anti-inflammatory drugs.
Data on 76 guidewire insertions into the pancreatic duct (6 in 5-minute EPBD group and 70 in 15-second EPBD group, respectively) and 63 difficult cannulations (11 in 5-minute EPBD group and 52 in 15-second EPBD group, respectively) were missing.
Short-term adverse events in the 5-minute and 15-second EPBD groups.
|
|
|
| |
| Overall | 21 (13.4) | 59 (13.1) | 0.999 |
|
Pancreatitis
| 13 (8.3) | 40 (8.9) | 0.871 |
Mild/moderate/severe | 10/0/3 | 29/9/2 | 0.091 |
| Cholangitis | 4 (2.5) | 14 (3.1) | 0.999 |
| Cholecystitis | 5 (3.2) | 4 (0.9) | 0.543 |
| Aspiration pneumonia | 1 (0.6) | 4 (0.9) | 0.999 |
| Liver abscess | 1 (0.6) | 1 (0.2) | 0.451 |
| Bleeding | 0 | 1 (0.2) | 0.999 |
| Retroperitoneal perforation | 1 (0.6) | 1 (0.2) | 0.451 |
| Basket impaction | 0 | 0 | NA |
Data are expressed as numbers and percentages of patients within a given group. EPBD, endoscopic papillary balloon dilation; NA, not available.
We included PEP associated with the first ERCP session only, as a study outcome.
Univariable analysis of risk factors for PEP.
|
| |||
|
|
|
| |
| Younger age (< 50 y) | 1.07 | 0.32 – 2.87 | 0.803 |
| Female sex | 1.41 | 0.76 – 2.58 | 0.239 |
| Periampullary diverticulum | 1.17 | 0.63 – 2.15 | 0.657 |
| Bile duct diameter < 10 mm | 1.12 | 0.61 – 2.05 | 0.773 |
| Stone diameter > 10 mm | 1.19 | 0.43 – 2.80 | 0.654 |
| Number of stones > 3 | 1.97 | 1.00 – 3.76 | 0.033 |
| Dilation balloon diameter < 10 mm | 0.81 | 0.37 – 1.97 | 0.545 |
| Peak pressure of the balloon > 4 atmospheres | 0.66 | 0.13 – 2.16 | 0.608 |
| 5-minute EPBD | 0.93 | 0.44 – 1.83 | 0.871 |
| Procedure time < 30 minutes | 0.82 | 0.35 – 1.71 | 0.728 |
| Lithotripsy | 1.00 | 0.42 – 2.17 | 0.999 |
| Complete stone removal during a single session | 0.97 | 0.49 – 2.04 | 0.999 |
| ERCP performed by trainees | 1.45 | 0.78 – 2.76 | 0.247 |
| Difficult cannulation (≥ 10 times or ≥ 10 minutes) | 1.91 | 0.98 – 3.63 | 0.041 |
| Pancreatic duct opacification | 3.01 | 1.45 – 5.98 | 0.002 |
| Guidewire insertion into the pancreatic duct | 2.11 | 1.14 – 3.96 | 0.012 |
| Number of guidewire insertions into the pancreatic duct > 3 times | 2.06 | 0.72 – 5.14 | 0.104 |
| NSAIDs | 1.12 | 0.38 – 2.80 | 0.812 |
| Pancreatic stent | 2.36 | 0.99 – 5.15 | 0.029 |
CI, confidence interval; EPBD, endoscopic papillary balloon dilation; ERCP, endoscopic retrograde cholangiopancreatography; NSAIDs, nonsteroidal anti-inflammatory drugs; OR, odds ratio; PEP, post-ERCP pancreatitis.
Multivariable analysis of risk factors for PEP.
|
| |||
|
|
|
| |
| 5-minute EPBD | 1.02 | 0.50 – 1.99 | 0.948 |
| Younger age (< 50 y) | 1.04 | 0.39 – 2.78 | 0.933 |
| Pancreatic duct opacification | 2.64 | 1.31 – 5.29 | 0.006 |
| Pancreatic stent | 1.67 | 0.74 – 3.75 | 0.216 |
CI, confidence interval; EPBD, endoscopic papillary balloon dilation; OR, odds ratio; PEP, post-ERCP pancreatitis.